IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Sarcomas
National Cancer Institute (NCI)protein_peptidePhase 1/2Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 29/ 100
- Competitive Position
- 95/ 100
Competitive context
109 Active assets in the Sarcomas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE National Cancer Institute (NCI) | Phase 2 | BB |
Cyclophosphamide Essen Biotech | Phase 2 | BB |
Ifosfamide City of Hope Medical Center | Phase 3 | BB |
Inno-206 City of Hope Medical Center | Phase 3 | BB |
Carboplatin OHSU Knight Cancer Institute | Phase 2 | BB |
View all 50 →
Same molecule, other indications
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →